How to buy Ayala Pharmaceuticals stock

Ayala Pharmaceuticals, Inc is a biotechnology business based in the US. Ayala Pharmaceuticals shares (AYLA) are listed on the NASDAQ and all prices are listed in US Dollars. Ayala Pharmaceuticals employs 34 staff and has a trailing 12-month revenue of around 0.00.

Ayala Pharmaceuticals share price

Use our graph to track the performance of AYLA stocks over time.

Ayala Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$8.62 - $23.99
50-day moving average	$11.40
200-day moving average	$12.57
Wall St. target price	$22.70
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Ayala Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Ayala Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Ayala Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ayala Pharmaceuticals financials

Revenue TTM	$3.7 million
Gross profit TTM	$1 million
Return on assets TTM	-56.5%
Return on equity TTM	-114.08%
Profit margin	0%
Book value	N/A
Market capitalisation	$139.5 million

TTM: trailing 12 months

Shorting Ayala Pharmaceuticals shares

There are currently 146,300 Ayala Pharmaceuticals shares held short by investors – that's known as Ayala Pharmaceuticals's "short interest". This figure is 42.6% up from 102,586 last month.

There are a few different ways that this level of interest in shorting Ayala Pharmaceuticals shares can be evaluated.

Ayala Pharmaceuticals's "short interest ratio" (SIR)

Ayala Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ayala Pharmaceuticals shares currently shorted divided by the average quantity of Ayala Pharmaceuticals shares traded daily (recently around 18901.80878553). Ayala Pharmaceuticals's SIR currently stands at 7.74. In other words for every 100,000 Ayala Pharmaceuticals shares traded daily on the market, roughly 7740 shares are currently held short.

However Ayala Pharmaceuticals's short interest can also be evaluated against the total number of Ayala Pharmaceuticals shares, or, against the total number of tradable Ayala Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ayala Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Ayala Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0219% of the tradable shares (for every 100,000 tradable Ayala Pharmaceuticals shares, roughly 22 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ayala Pharmaceuticals.

Find out more about how you can short Ayala Pharmaceuticals stock.

Ayala Pharmaceuticals share dividends

We're not expecting Ayala Pharmaceuticals to pay a dividend over the next 12 months.

Ayala Pharmaceuticals overview

Ayala Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Frequently asked questions

• What percentage of Ayala Pharmaceuticals is owned by insiders or institutions?

  Currently 53.776% of Ayala Pharmaceuticals shares are held by insiders and 29.419% by institutions.

• How many people work for Ayala Pharmaceuticals?

  Latest data suggests 34 work at Ayala Pharmaceuticals.

• When does the fiscal year end for Ayala Pharmaceuticals?

  Ayala Pharmaceuticals's fiscal year ends in December.

• Where is Ayala Pharmaceuticals based?

  Ayala Pharmaceuticals's address is: 4 Oppenheimer Street, Rehovot, Israel, 7670104

• What is Ayala Pharmaceuticals's ISIN number?

  Ayala Pharmaceuticals's international securities identification number is: US05465V1089

• What is Ayala Pharmaceuticals's CUSIP number?

  Ayala Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05465V108